实用肝脏病杂志2024，Vol.27Issue(4)：591-594,4.DOI:10.3969/j.issn.1672-5069.2024.04.025
卡瑞利珠单抗联合阿帕替尼治疗晚期原发性肝癌患者效果研究
Should the camrelizumab in combination with apatinib in the treatment of patients with advanced primary liver cancer benefit?
摘要
Abstract
Objective The aim of this study was to explore the efficacy of camrelizumab and apatinib combination in the treatment of patients with advanced primary liver cancer(PLC).Methods 62 patients with advanced PLC were enrolled in our hospital between August 2018 and August 2021,and were divided randomly into control group(n=31)and observation group(n=31),receiving apatinib or camrelizumab and apatinib combination therapy for three months.The percentages of peripheral blood T lymphocyte subsets were detected by flow cytometry,and serum alpha-fetoprotein(AFP),heat shock protein 90α(HSP90α)and carcinoembryonic antigen(CEA)levels were detected by electrochemiluminescence.Results At the end of 3 month treatment,the objective remission rates in the observation and control group were 58.1%and 32.3%,respectively(P<0.05);the percentage of peripheral blood CD4+cells and the ratio of CD4+/CD8+cells in the observation group were(38.3±2.6)%and(1.3±0.2),both significantly higher than[(34.5±2.9)%and(1.1±0.2),P<0.05]in the control;serum AFP,HSP90α and CEA levels were(143.6±26.5)μg/L,(93.2±22.4)ng/mL and(13.2±4.3)ng/mL,all much lower than[(204.5±29.6)μg/L,(129.1±23.5)ng/mL and(28.6±4.8)ng/mL,respectively,P<0.05]in the control;the mean overall survivals in the two groups were 14 months and 10 months(Log Rank x2=5.033,P=0.025).Conclusion The combination of camrelizumab and apatinib therapy has a certain clinical efficacy in the treatment of patients with advanced PLC,which might slightly safely prolong the survival.关键词
原发性肝癌/晚期/卡瑞利珠单抗/阿帕替尼/总生存期/治疗Key words
Hepatoma/Advanced/Camrelizumab/Apatinib/Overall survival/Therapy引用本文复制引用
王秀芝,常金,宋丹,谭亭昭..卡瑞利珠单抗联合阿帕替尼治疗晚期原发性肝癌患者效果研究[J].实用肝脏病杂志,2024,27(4):591-594,4.基金项目
山东省医药卫生科技发展计划项目(编号:2018WS119) （编号:2018WS119）
